Market revenue in 2023 | USD 711.7 million |
Market revenue in 2030 | USD 1,181.1 million |
Growth rate | 7.5% (CAGR from 2023 to 2030) |
Largest segment | Otc rdt |
Fastest growing segment | OTC RDT |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | OTC RDT, Professional RDT |
Key market players worldwide | ACON Laboratories, Abbott Laboratories, BD, BioMerieux SA, Bio-Rad Laboratories Inc, Danaher Corp, Cardinal Health Inc, Creative Diagnostics, Roche, McKesson Corp, Meridian Bioscience, Trinity Biotech PLC ADR, Zoetis Inc Class A, Artron Bioresearch, Alfa Medical Group, BioNTech SE ADR, Sight Diagnostics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rapid medical diagnostic kits market will help companies and investors design strategic landscapes.
Otc rdt was the largest segment with a revenue share of 63.14% in 2023. Horizon Databook has segmented the Japan rapid medical diagnostic kits market based on otc rdt, professional rdt covering the revenue growth of each sub-segment from 2018 to 2030.
Rise in collaborations among new market entrants is anticipated to boost market growth during the forecast period. For instance, in July 2019, Chembio Diagnostics collaborated with Shire Human Genetic Therapies, Inc. to develop a new diagnostic test.
This is a blood test that would help detect biomarkers or substances that show an infection or disease in the body. Shire is a subsidiary of Takeda Pharmaceuticals; therefore, this project will be funded by Takeda itself. Thus, rise in collaborations among new market entrants to develop new diagnostic tests is anticipated to fuel the market during the forecast period.
Increase in investments from a private organization to develop diagnostic tests is expected to boost market growth during the forecast period. For instance, in September 2018, the Global Health Innovative Technology Fund announced an investment of USD 3.8 million to Fujifilm Corporation based in Japan as well as Switzerland’s Foundation for Innovative New Diagnostics to develop a highly sensitive rapid diagnostic test TB-LAM for detection of TB.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan rapid medical diagnostic kits market , including forecasts for subscribers. This country databook contains high-level insights into Japan rapid medical diagnostic kits market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account